New hope for rare cancer: immune booster plus chemo shows promise

NCT ID NCT04339738

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This phase II trial tests whether adding the immunotherapy drug nivolumab to the chemotherapy paclitaxel helps shrink tumors in people with angiosarcoma who haven't had taxane drugs before. For those who have already received taxanes, the trial tests a combination of nivolumab and cabozantinib. The study aims to see if these combinations can stop the cancer from growing or coming back. About 90 participants are enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Paclitaxel, Nivolumab, Cabozantinib
What this could lead to: If successful, this could lead to a new combination treatment that shrinks angiosarcoma tumors and delays their return.
What could go wrong: This is a phase II trial with only 90 participants, so results may not apply to everyone. The drugs can cause side effects like immune reactions or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Nov 2020

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed cutaneous or visceral angiosarcoma, where curative treatment is either not possible or curative modality therapy is declined by the subject. Note: If a subject declines curative modality therapy, the reason must be documented (e.g. excessive morbidity to necessary surgery) * Note: Radiation induced angiosarcomas are permitted * All local diagnostic slides AND 5 x 4-6 micron unstained slides from diagnostic tumor tissue should be available for retrospective central pathology review * Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Per RECIST v1.1, clinical lesions will only be considered measurable when they are superficial and \>= 10 mm diameter as assessed using calipers or ruler (e.g. skin nodules). For the case of skin lesions, documentation by color photography including a ruler to estimate the size of the lesion is required. When lesions can be evaluated by both clinical exam and imagining, imaging evaluation should be undertaken since it is more objective and may also be reviewed at the end of the study. The same method of measurement should be used throughout the study, preferably performed by the same investigator. Areas previously radiated must have demonstrated disease progression at some point over the past 6 months and growth must be subsequent to the last line of anti-cancer directed therapy (e.g. chemotherapy, radiation therapy, surgery) * Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown * Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 3 days prior to registration is required * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Prior Treatment * Patient must have completed all prior cancer directed therapies (including investigational) \>= 7 days prior to cycle 1 day 1 * Exception: prostate patients who are allowed to concurrently receive androgen suppression therapy * Note: Radiation therapy must be completed \>= 7 days of day 1 of study treatment, and must not be expected to significantly impact blood count recovery * There is no limit to overall number of prior lines of therapy * No prior PD-1 inhibitor or PD-L1 inhibitor therapy is permitted * No prior administration of VEGF TKI therapy is permitted * Recovery to baseline or' =\< grade 1 CTCAE version 5.0 from toxicity related to any prior treatment, unless adverse events are clinically non-significant and/or stable on supportive therapy, with the exception of fatigue (which should be =\< grade 2) or alopecia. Note: Patients should be expected to have experienced any nadir and have adequate blood count recovery prior to cycle 1 day 1 * Taxane Naive Patients Only: No prior exposure to taxane therapy of any duration for angiosarcoma * Taxane Pre-treated Patients Only (Effective 10/28/2021, new patient accrual to Arm 3 was permanently closed): Prior taxane therapy is allowed at any point prior to registration as long as prior treatment eligibility criteria are met prior to cycle 1 day 1 * No major surgery (except the diagnostic biopsy) =\< 28 days of study registration. Procedures such as thoracentesis, paracentesis, percutaneous biopsy, Lasik eye surgery are not considered major surgery. Subjects with clinically relevant ongoing complications from prior surgery are not eligible * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Hemoglobin \>= 9.0 g/dL * Calculated (Calc.) creatinine clearance \>= 30 mL/min (per Cockcroft-Gault) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) * For patients with documented/suspected Gilbert's disease, bilirubin =\< 3 x ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN) * For patients with significant hepatic metastases, ALT and AST =\< 5 x ULN. No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction * Urine protein:creatinine (UPC) ratio \< 1 or urine protein =\< 1+ (Only for Arm 3 Taxane pre-treated and crossover patients) * No uncontrolled central nervous system (CNS) metastases. Patients with history of CNS metastasis will be allowed as long as the metastatic sites were adequately treated as demonstrated by clinical and radiographic improvement, and the patient has recovered from the intervention (no residual adverse events \> CTCAE grade 1), and the patient has remained without recurrence of new or worsening CNS symptoms for a period of 28 days prior to registration. Treated CNS metastasis (mets) should have no ongoing requirement for steroids, and no evidence of hemorrhage after treatment for at least 28 days prior to registration * No uncontrolled intercurrent illness that would put the patient at undue risk by participation in the study, in the opinion of the investigator * No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, history of Mobitz II second degree or third degree heart block without a permanent pacemaker in place, myocardial ischemia or infarction, severe or unstable angina, New York Heart Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months * No thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 1 month before randomization. Subjects with a diagnosis of incidental, subsegmental pulmonary embolism (PE) or deep vein thrombosis (DVT) within 6 months are allowed if stable, asymptomatic, and treated with low molecular weight heparin (LMWH) for at least 2 weeks before first dose. Iatrogenic arterial embolization procedures such as tumor arterial embolization or splenic artery embolization are allowed * Patients with a requirement for steroid treatment or other immunosuppressive treatment: Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted * Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event) * Active autoimmune disease requiring systemic treatment (i.e. disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These include but are not limited to patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease * Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * No planned palliative procedures for alleviation of pain such as radiation therapy or surgery * No untreated or impending spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression * No known or suspected contraindications or hypersensitivity to paclitaxel, cabozantinib or nivolumab or to any of the excipients * Disorders associated with a high risk of perforation or fistula formation: active inflammatory bowel disease, active diverticulitis, active cholecystitis, active symptomatic cholangitis or active appendicitis, active acute pancreatitis or active acute obstruction of the pancreatic or biliary duct, or active gastric outlet obstruction; abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before randomization. Note: Complete healing of an intra-abdominal abscess must be confirmed before randomization * No clinically significant hematuria, hematemesis, or hemoptysis, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 3 months before randomization * No lesions invading major pulmonary blood vessels * No other clinically significant disorders: uncompensated/symptomatic hypothyroidism; requirements for hemodialysis or peritoneal dialysis; history of solid organ transplantation * Serious non-healing wounds unrelated to cancer are excluded * Note: Wounds that are cutaneous angiosarcoma are allowed * Chronic concomitant treatment with strong inhibitors and inducers of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors and inducers must discontinue the drug 7 days and 14 days, respectively prior to registration on the study * Taxane Naive Patients Only: No clinically significant neuropathy (grade \>= 2 per NCI CTCAE v5.0) * Taxane Pre-treated only (Effective 10/28/2021, new patient accrual to Arm 3 was permanently closed): * Stroke (including transient ischemic attack \[TIA\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 6 months before first dose. Subjects with a diagnosis of DVT within 6 months are allowed if stable and treated with LMWH for at least 2 weeks before first dose * No history of clinically significant coagulopathy * No uncontrolled hypertension, defined as systolic blood pressure of \> 140 mmHg or diastolic pressure \> 90 mmHg on anti-hypertensive medications * No known or suspected gastrointestinal disorder affecting absorption of oral medications (for patients getting cabozantinib) * No clinical, laboratory or radiographic evidence of an active bacterial, fungal, or viral infection requiring treatment at the time of registration. No concurrent use of parenteral (IV) antibiotics is permitted. Oral antibiotics administered for a defined course with expectation of resolution of infection are permitted at the discretion of the investigator * No use of ongoing systemic steroid therapy within 7 days prior to study registration. Dose equivalence of prednisone 10mg daily or less is permitted * Taxane Pre-treated only: * No current use of aspirin (\> 81 mg/day), or any other antiplatelet agents * Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin inhibitors, and factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) is not permitted. Low-dose (prophylactic) low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects with no known brain metastases, no clinically significant hemorrhage, or no complications from a thromboembolic event on the anticoagulation regimen, and who have been on a stable dose of LMWH for at least 2 weeks before first dose * Patients must be able to speak and comprehend English or Spanish in order to complete the mandatory patient-completed measures * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown * Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 3 days prior to re-registration is required * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Age \>= 18 years * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): ECOG performance status 0-1 * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Prior Treatment * Patient must have completed all prior treatments (including investigational Arm 2 paclitaxel) \>= 28 days prior to cycle 1 day 1 * Exception: prostate patients who are allowed to concurrently receive androgen suppression therapy * Note: Re-registration is only permitted after progression on Arm 2 * No prior PD-1 inhibitor or PD-L1 inhibitor therapy is permitted * Recovery to baseline, or =\< grade 1 CTCAE version 5.0 from toxicity related to any prior treatment, unless adverse events are clinically non-significant and/or stable on supportive therapy, with the exception of fatigue (which should be =\< grade 2) or alopecia. Note: Patients should be expected to have experienced any nadir and have adequate blood count recovery prior to cycle 1 day 1 * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No major surgery (except the diagnostic biopsy) =\< 28 days of study re-registration. Procedures such as thoracentesis, paracentesis, percutaneous biopsy, Lasik eye surgery are not considered major surgery. Subjects with clinically relevant ongoing complications from prior surgery are not eligible * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Platelet count \>= 100,000/mm\^3 * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Hemoglobin \>= 9.0 g/dL * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Calc. creatinine clearance \>= 30 mL/min (per Cockcroft-Gault) * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Total bilirubin =\< 1.5 x upper limit of normal (ULN) * For patients with documented/suspected Gilbert's disease, bilirubin =\< 3 x ULN * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): AST/ALT =\< 2.5 x upper limit of normal (ULN) * For patients with significant hepatic metastases, ALT and AST =\< 5 x ULN. No clinically active or chronic liver disease resulting in moderate/severe hepatic impairment (Child-Pugh class B or C), ascites, coagulopathy or bleeding due to liver dysfunction * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): UPC ratio \< 1 or urine protein =\< 1+ * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No uncontrolled CNS metastases. Patients with history of CNS metastasis will be allowed as long as the metastatic sites were adequately treated as demonstrated by clinical and radiographic improvement, and the patient has recovered from the intervention (no residual adverse events \> CTCAE grade 1), and the patient has remained without recurrence of new or worsening CNS symptoms for a period of 28 days prior to registration. Treated CNS mets should have no ongoing requirement for steroids, and no evidence of hemorrhage after treatment for at least 28 days prior to registration * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No uncontrolled intercurrent illness that would put the patient at undue risk by participation in the study, in the opinion of the investigator * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No history of syncope of cardiovascular etiology, uncontrolled cardiac arrhythmia, History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place, myocardial ischemia or infarction, severe or unstable angina, New York Heart Association (NYHA) class II to IV heart failure, or stroke/transient ischemic attack (TIA) within the past 3 months * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 1 month before randomization. Subjects with a diagnosis of incidental, subsegmental PE or DVT within 6 months are allowed if stable, asymptomatic, and treated with LMWH for at least 2 weeks before first dose. Iatrogenic arterial embolization procedures such as tumor arterial embolization or splenic artery embolization are allowed * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Patients with a requirement for steroid treatment or other immunosuppressive treatment: Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): Active autoimmune disease requiring systemic treatment (i.e. disease modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. These include but are not limited to patients with a history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as SLE, rheumatoid arthritis, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease * Note: Patients are permitted to enroll if they have vitiligo; type I diabetes mellitus; hypothyroidism, pituitary or adrenal insufficiency requiring only hormone replacement; psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event) * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No planned palliative procedures for alleviation of pain such as radiation therapy or surgery * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No untreated or impending spinal cord compression or evidence of spinal metastases with a risk of impending fracture or spinal cord compression * Re-Registration Eligibility Criteria (upon progression on Arm 2 only): No known or suspected contraindications or hypersensitivity to cabozantinib or nivolumab or to any of the exc

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angiosarcoma skin angiosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Skin angiosarcoma Skin radiation-related angiosarcoma Visceral angiosarcoma

Contacts and locations

Locations

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407, United States
Atrium Health Pineville/LCI-Pineville

Charlotte, North Carolina, 28210, United States
Banner University Medical Center - Tucson

Tucson, Arizona, 85719, United States
Cambridge Medical Center

Cambridge, Minnesota, 55008, United States
Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017, United States
Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, 73505, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle Physician Group-Effingham

Effingham, Illinois, 62401, United States
Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States
Carle at The Riverfront

Danville, Illinois, 61832, United States
Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203, United States
Castle Medical Center

Kailua, Hawaii, 96734, United States
Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613, United States
Central Care Cancer Center - Garden City

Garden City, Kansas, 67846, United States
Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
CoxHealth South Hospital

Springfield, Missouri, 65807, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Divine Providence Hospital

Williamsport, Pennsylvania, 17754, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Emory University Hospital Midtown

Atlanta, Georgia, 30308, United States
FHP Health Center-Guam

Tamuning, 96913, Guam
Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369, United States
Fairview Lakes Medical Center

Wyoming, Minnesota, 55092, United States
Fairview Northland Medical Center

Princeton, Minnesota, 55371, United States
Fairview Ridges Hospital

Burnsville, Minnesota, 55337, United States
Fairview Southdale Hospital

Edina, Minnesota, 55435, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Freeman Health System

Joplin, Missouri, 64804, United States
Gibbs Cancer Center-Gaffney

Gaffney, South Carolina, 29341, United States
Gibbs Cancer Center-Pelham

Greer, South Carolina, 29651, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Hawaii Cancer Care - Westridge

‘Aiea, Hawaii, 96701, United States
Hawaii Cancer Care Inc - Waterfront Plaza

Honolulu, Hawaii, 96813, United States
Hawaii Cancer Care Inc-Liliha

Honolulu, Hawaii, 96817, United States
Hawaii Diagnostic Radiology Services LLC

Honolulu, Hawaii, 96817, United States
Health Partners Inc

Minneapolis, Minnesota, 55454, United States
Heartland Regional Medical Center

Saint Joseph, Missouri, 64506, United States
Hennepin County Medical Center

Minneapolis, Minnesota, 55415, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Island Urology

Honolulu, Hawaii, 96813, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826, United States
Kuakini Medical Center

Honolulu, Hawaii, 96817, United States
LSU Health Sciences Center at Shreveport

Shreveport, Louisiana, 71103, United States
Lakeview Hospital

Stillwater, Minnesota, 55082, United States
Marshfield Medical Center - Minocqua

Minocqua, Wisconsin, 54548, United States
Marshfield Medical Center - Weston

Weston, Wisconsin, 54476, United States
Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701, United States
Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449, United States
Marshfield Medical Center-Rice Lake

Rice Lake, Wisconsin, 54868, United States
Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482, United States
Mary Greeley Medical Center

Ames, Iowa, 50010, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
McFarland Clinic - Ames

Ames, Iowa, 50010, United States
McFarland Clinic - Boone

Boone, Iowa, 50036, United States
McFarland Clinic - Jefferson

Jefferson, Iowa, 50129, United States
McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158, United States
McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401, United States
Mercy Hospital

Coon Rapids, Minnesota, 55433, United States
Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903, United States
Mercy Hospital Joplin

Joplin, Missouri, 64804, United States
Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120, United States
Mercy Hospital Saint Louis

St Louis, Missouri, 63141, United States
Mercy Hospital South

St Louis, Missouri, 63128, United States
Mercy Hospital Springfield

Springfield, Missouri, 65804, United States
Mercy Hospital Washington

Washington, Missouri, 63090, United States
Mercy Infusion Center - Chippewa

St Louis, Missouri, 63109, United States
Mercy Oncology and Hematology - Clayton-Clarkson

Ballwin, Missouri, 63011, United States
Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337, United States
Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109, United States
Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Moffitt Cancer Center - McKinley Campus

Tampa, Florida, 33612, United States
Moffitt Cancer Center-International Plaza

Tampa, Florida, 33607, United States
Monticello Cancer Center

Monticello, Minnesota, 55362, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
Nebraska Methodist Hospital

Omaha, Nebraska, 68114, United States
New Ulm Medical Center

New Ulm, Minnesota, 56073, United States
North Grove Medical Park

Spartanburg, South Carolina, 29303, United States
North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422, United States
NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201, United States
NorthShore University HealthSystem-Glenbrook Hospital

Glenview, Illinois, 60026, United States
NorthShore University HealthSystem-Highland Park Hospital

Highland Park, Illinois, 60035, United States
Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042, United States
Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134, United States
Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115, United States
Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555, United States
Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045, United States
Northwestern University

Chicago, Illinois, 60611, United States
OSF Saint Anthony's Health Center

Alton, Illinois, 62002, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Pali Momi Medical Center

‘Aiea, Hawaii, 96701, United States
Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States
Parkview Regional Medical Center

Fort Wayne, Indiana, 46845, United States
Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401, United States
Queen's Cancer Cenrer - POB I

Honolulu, Hawaii, 96813, United States
Queen's Cancer Center - Kuakini

Honolulu, Hawaii, 96817, United States
Queen's Cancer Center - Pearlridge

‘Aiea, Hawaii, 96701, United States
Queen's Medical Center

Honolulu, Hawaii, 96813, United States
Regions Hospital

Saint Paul, Minnesota, 55101, United States
Rice Memorial Hospital

Willmar, Minnesota, 56201, United States
Ridgeview Medical Center

Waconia, Minnesota, 55387, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rush MD Anderson Cancer Center

Chicago, Illinois, 60612, United States
Rush-Copley Healthcare Center

Yorkville, Illinois, 60560, United States
Rush-Copley Medical Center

Aurora, Illinois, 60504, United States
SMC Center for Hematology Oncology Union

Union, South Carolina, 29379, United States
SSM Health Good Samaritan

Mount Vernon, Illinois, 62864, United States
Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379, United States
Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Smilow Cancer Hospital Care Center - Guilford

Guilford, Connecticut, 06437, United States
Smilow Cancer Hospital Care Center - Waterford

Waterford, Connecticut, 06385, United States
Smilow Cancer Hospital Care Center - Westerly

Westerly, Rhode Island, 02891, United States
Smilow Cancer Hospital Care Center at Glastonbury

Glastonbury, Connecticut, 06033, United States
Smilow Cancer Hospital Care Center at Greenwich

Greenwich, Connecticut, 06830, United States
Smilow Cancer Hospital Care Center at Saint Francis

Hartford, Connecticut, 06105, United States
Smilow Cancer Hospital Care Center-Fairfield

Fairfield, Connecticut, 06824, United States
Smilow Cancer Hospital Care Center-Trumbull

Trumbull, Connecticut, 06611, United States
Smilow Cancer Hospital-Derby Care Center

Derby, Connecticut, 06418, United States
Smilow Cancer Hospital-Orange Care Center

Orange, Connecticut, 06477, United States
Smilow Cancer Hospital-Torrington Care Center

Torrington, Connecticut, 06790, United States
Smilow Cancer Hospital-Waterbury Care Center

Waterbury, Connecticut, 06708, United States
Spartanburg Medical Center

Spartanburg, South Carolina, 29303, United States
Spartanburg Medical Center - Mary Black Campus

Spartanburg, South Carolina, 29307, United States
Straub Clinic and Hospital

Honolulu, Hawaii, 96813, United States
Straub Medical Center - Kahului Clinic

Kahului, Hawaii, 96732, United States
The Cancer Center of Hawaii-Liliha

Honolulu, Hawaii, 96817, United States
The Cancer Center of Hawaii-Pali Momi

‘Aiea, Hawaii, 96701, United States
The Carle Foundation Hospital

Urbana, Illinois, 61801, United States
The Queen's Medical Center - West Oahu

‘Ewa Beach, Hawaii, 96706, United States
Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States
UCHealth University of Colorado Hospital

Aurora, Colorado, 80045, United States
UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146, United States
UPMC Susquehanna

Williamsport, Pennsylvania, 17701, United States
UPMC-Saint Margaret

Pittsburgh, Pennsylvania, 15215, United States
United Hospital

Saint Paul, Minnesota, 55102, United States
Unity Hospital

Fridley, Minnesota, 55432, United States
University of Arizona Cancer Center-North Campus

Tucson, Arizona, 85719, United States
University of Arizona Cancer Center-Orange Grove Campus

Tucson, Arizona, 85704, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Hawaii Cancer Center

Honolulu, Hawaii, 96813, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Utah Sugarhouse Health Center

Salt Lake City, Utah, 84106, United States
University of Washington Medical Center - Montlake

Seattle, Washington, 98195, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States
Vanderbilt Breast Center at One Hundred Oaks

Nashville, Tennessee, 37204, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Vanderbilt-Ingram Cancer Center Cool Springs

Franklin, Tennessee, 37067, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wilcox Memorial Hospital and Kauai Medical Clinic

Lihue, Hawaii, 96766, United States
Yale University

New Haven, Connecticut, 06520, United States
Yale-New Haven Hospital North Haven Medical Center

North Haven, Connecticut, 06473, United States